Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022-Reference-Cited by-同舟云学术

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Published:2022-09-29 Issue:39 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Barda Noam¹²³^ORCID,Canetti Michal⁴⁵^ORCID,Gilboa Mayan⁴⁵,Indenboim Victoria⁶⁴,Asraf Keren⁷⁴,Weiss-Ottolenghi Yael⁴⁵,Amit Sharon⁸⁴,Zibly Daniel⁵,Doolman Ram⁶⁴,Mendelson Ella⁷⁴,Harats Dror⁹⁴,Freedman Laurence S.¹⁰,Kreiss Yitshak⁹⁴,Lustig Yaniv⁶⁴,Regev-Yochay Gili⁴⁵

Affiliation:

1. Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be’er Sheva, Israel

2. ARC Innovation Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

3. Epidemiology, Biostatistics and Community Health Services, Ben-Gurion University of the Negev, Be’er Sheva, Israel

4. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel

5. The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

6. Central Virology Laboratory, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat Gan, Israel

7. The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel

8. Clinical Microbiology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

9. General Management, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

10. Biostatistics and Biomathematics Unit, Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27–1.97) in Spikevax and 1.16-fold (95% CI: 0.98–1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62–1.09) and Comirnaty (0.86; 95% CI: 0.65–1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13–0.62) and 0.51 (95% CI: 0.27–0.96), respectively.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference14 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.;Polack;N Engl J Med,2020

2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.;Baden;N Engl J Med,2021

3. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.;Regev-Yochay;N Engl J Med,2022

4. Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up.;Canetti;Research Square,2022

5. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, clinical efficacy and safety of additional second COVID‐19 booster vaccines against Omicron and its subvariants: A systematic review;Reviews in Medical Virology;2024-01

2. Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study;Science Advances;2023-12-22

3. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults;Nature Communications;2023-08-08

4. Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study;2023-06-28

5. Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine;Vaccines;2023-04-25